Phase 1 Protocol for phase 1 HIV clinical study
This is a Pilot Study (Phase I/II) testing the immunologic activity and safety of AGS-004, an autologous HIV immunotherapeutic, in HIV-infected adults on HAART.
Study Design: Patients that are successfully treated with highly active anti-retroviral therapy (HAART) with no measurable viral load AND have a cryopreserved infectious plasma sample that was drawn immediately prior to initiation of HAART will be administered 4 monthly doses of the Arcelis product.
protocol
Clinical protocol
Phase 1 HIV clinical study
HIV antigen
Charles Nicolette
Arcelis therapeutic platform
blood plasma
7 HIV patients
Phase 2a Protocol for the Phase 2 HIV study